NCT01609218

A Study of LY2140023 in Healthy Participants

A Study to Evaluate the Impact of Activated Charcoal on the Absorption of LY2140023 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Denovo Biopharma LLC · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The study will evaluate the effect of activated charcoal on absorption of LY2140023. The study involves a single dose of 80 milligrams (mg) LY2140023 taken as 1 tablet by mouth 2 times during study (once with activated charcoal, once without activated charcoal). This study will last approximately 16 days, not including screening. Screening is required within 28 days prior to study entry.

Conditions

• Healthy Volunteer Study

Interventions

Type	Name	Description
DRUG	LY2140023
DRUG	Aqueous activated charcoal

Timeline

• Start date: 2012-06-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2012-05-31
• Last updated: 2021-09-21
• Results posted: 2021-09-21

Locations

1 site across 1 country: United Kingdom